Haemonetics Corporation [NYSE:HAE]: Analyst Rating and Earnings

Pro stock traders frequently make sure to pay attention what expert market analysts are saying about a potential stock buy. Regarding Haemonetics Corporation [HAE] right now, the most recent ratings from Wall St. analysts that we can see right now is regarding the quarter that’s slated to end in March. On average, stock market experts give HAE an Outperform rating. Its stock price has been found in the range of 0.95 to 6.77. This is compared to its latest closing price of $85.03.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Haemonetics Corporation [HAE] is sitting at 2.38. This is compared to 1 month ago, when its average rating was 2.38.

For the quarter ending in Dec-18 Haemonetics Corporation [HAE] generated $0.25 billion in sales. That’s 1.11% lower than the average estimate of $0.25 billion as provided by Wall Street analysts. The three indicators above suggest that on the whole, this stock is not presenting an attractive investment option, as there are too many red flags that don’t point to a high-value ROI.

Keep your eyes peeled for the next scheduled financial results to be made public for this company, which are scheduled to be released on Tue 14 May (In 93 Days).

Fundamental Analysis of Haemonetics Corporation [HAE]

Now let’s turn to look at profitability: with a current Operating Margin for Haemonetics Corporation [HAE] sitting at +11.81 and its Gross Margin at +46.11, this company’s Net Margin is now 2.30%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This company’s Return on Total Capital is 10.37, and its Return on Invested Capital has reached 7.70%. Its Return on Equity is 6.11, and its Return on Assets is 3.68. These metrics suggest that this Haemonetics Corporation does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Haemonetics Corporation [HAE] has generated a Total Debt to Total Equity ratio of 33.72. Similarly, its Total Debt to Total Capital is 25.21, while its Total Debt to Total Assets stands at 20.50. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 7.90, and its Long-Term Debt to Total Capital is 5.91. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.

What about valuation? This company’s Enterprise Value to EBITDA is 25.93 and its Total Debt to EBITDA Value is 1.29. The Enterprise Value to Sales for this firm is now 5.26, and its Total Debt to Enterprise Value stands at 0.06. Haemonetics Corporation [HAE] has a Price to Book Ratio of 5.09, a Price to Cash Flow Ratio of 17.76 and P/E Ratio of 95.87. These metrics show that this company has a mixed appeal, and ROI could be a gain or a loss.

Shifting the focus to workforce efficiency, Haemonetics Corporation [HAE] earns $288,241 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 5.95 and its Total Asset Turnover is 0.73. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 0.94 and its Current Ratio is 1.35. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Performance Indicators

Let’s now turn our attention to trading performance: Haemonetics Corporation [HAE] has 51.86M shares outstanding, amounting to a total market cap of $4.32B. Its stock price has been found in the range of 68.08 to 117.56. At its current price, it has moved by -29.18% from its 52-week high, and it has moved 22.28% from its 52-week low.

This stock’s Beta value is currently 0.93, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 25.10. This stock, according to these metrics, is currently Oversold.

Conclusion: Is Haemonetics Corporation [HAE] a Reliable Buy?

Haemonetics Corporation [HAE] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.